Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Elisabeth Bolton-Gillespie"'
Autor:
Katherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, Samantha Langer, Micheal Siciliano, Margaret Nieborowska-Skorska, Kritika Hanamshet, Elizaveta A. Belyaeva, Andrea J. Bernhardy, Jaewong Lee, Morgan Moore, Huaqing Zhao, Peter Valent, Ksenia Matlawska-Wasowska, Markus Müschen, Smita Bhatia, Ravi Bhatia, Neil Johnson, Mariusz A. Wasik, Alexander V. Mazin, Tomasz Skorski
Publikováno v:
Cell Reports, Vol 23, Iss 11, Pp 3127-3136 (2018)
Summary: PARP inhibitors (PARPis) have been used to induce synthetic lethality in BRCA-deficient tumors in clinical trials with limited success. We hypothesized that RAD52-mediated DNA repair remains active in PARPi-treated BRCA-deficient tumor cells
Externí odkaz:
https://doaj.org/article/1a69e9155c374fdf8f71032c02246403
Autor:
Amy Tarangelo, Gerald Wertheim, Elisabeth Bolton-Gillespie, Katharina E. Hayer, Madhumita Jambhekar, Ying Cheng, Linh Le, Connie Ma, Xiongwei Cai, Patrick Viatour, Wei Tong, Pichai Raman, Nancy A. Speck, Eunsun Kim
Publikováno v:
The Journal of Experimental Medicine
The mechanisms regulating the homeostasis of HSCs remain poorly understood. Here, Kim et al. identify the Rb/E2f module as a central molecular hub in the regulation of cell cycle and homeostasis in HSCs. This mechanism drives the enforced differentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09943844eaf012bb1d052be3ff34a1ef
https://doi.org/10.1084/jem.20160719
https://doi.org/10.1084/jem.20160719
Autor:
Elizaveta A. Belyaeva, Morgan Moore, Ksenia Matlawska-Wasowska, Peter Valent, Huaqing Zhao, Elisabeth Bolton-Gillespie, Neil Johnson, Kritika Hanamshet, Yashodhara Dasgupta, Mariusz A. Wasik, Margaret Nieborowska-Skorska, Micheal Siciliano, Alexander V. Mazin, Samantha Langer, Andrea J. Bernhardy, Katherine Sullivan-Reed, Tomasz Skorski, Markus Müschen, Ravi Bhatia, Smita Bhatia, Jaewong Lee
Publikováno v:
Cell reports
Cell Reports, Vol 23, Iss 11, Pp 3127-3136 (2018)
Cell Reports, Vol 23, Iss 11, Pp 3127-3136 (2018)
SUMMARY PARP inhibitors (PARPis) have been used to induce synthetic lethality in BRCA-deficient tumors in clinical trials with limited success. We hypothesized that RAD52-mediated DNA repair remains active in PARPi-treated BRCA-deficient tumor cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103ef856ceb7fd583baf5fa7816aa2fa
https://pubmed.ncbi.nlm.nih.gov/29898385
https://pubmed.ncbi.nlm.nih.gov/29898385
Autor:
Mukta Asnani, Yoseph Barash, Ammar S. Naqvi, Katharina E. Hayer, Sisi Zheng, Andrei Thomas-Tikhonenko, Elisabeth Bolton-Gillespie
Publikováno v:
Blood. 134:1342-1342
Pediatric B-cell acute lymphoblastic leukemias (B-ALL) are striking for their low mutational burdens. Ostensibly, this paucity of mutation-associated neoantigens could limit the development of novel immunotherapies. However, our lab has previously sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2de7cac09b97d6a3b4ba3bb953834d0
https://doi.org/10.1182/blood-2019-131277
https://doi.org/10.1182/blood-2019-131277
Autor:
Thoralf Lange, Ilona Seferynska, Sylwia Flis, Steffen Koschmieder, Ravi Bhatia, Tomasz Skorski, Grazyna Hoser, Linda Kerstiens, Hardik Modi, Martin C. Müller, Jacqueline Maier, Tessa L. Holyoake, Elisabeth Bolton-Gillespie, Mateusz Koptyra, Mirle Schemionek, Tomasz Stoklosa, Margaret Nieborowska-Skorska, Hans-Ulrich Klein
Publikováno v:
Blood. 121:4175-4183
Genomic instability is a hallmark of chronic myeloid leukemia in chronic phase (CML-CP) resulting in BCR-ABL1 mutations encoding resistance to tyrosine kinase inhibitors (TKIs) and/or additional chromosomal aberrations leading to disease relapse and/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0160882ddcce32b069caa64870054db2
https://doi.org/10.1182/blood-2012-11-466938
https://doi.org/10.1182/blood-2012-11-466938
Autor:
Silvia Maifrede, Grazyna Hoser, Vera Gorbunova, Elisabeth Bolton-Gillespie, Tomasz Stoklosa, Kimberly Cramer-Morales, Sabine Cerny-Reiterer, Katarzyna Piwocka, Curt I. Civin, Jean C.Y. Wang, John E. Dick, Katherine J. Sullivan, Jaewong Lee, Peter Valent, Ravi Bhatia, Ilona Seferynska, Daniela Di Marcantonio, Huaqing Zhao, Yashodhara Dasgupta, Kolja Eppert, Margaret Nieborowska-Skorska, Daniel Gritsyuk, Stephen M. Sykes, Markus Müschen, Smita Bhatia, Min Li, Esteban Martínez, Tomasz Skorski, Mark D. Minden, Artur Slupianek, Lars Bullinger, Paulina Podszywalow-Bartnicka
Publikováno v:
Journal of Clinical Investigation
Quiescent and proliferating leukemia cells accumulate highly lethal DNA double-strand breaks that are repaired by 2 major mechanisms: BRCA-dependent homologous recombination and DNA-dependent protein kinase-mediated (DNA-PK-mediated) nonhomologous en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e08ca337e7c40848d7b5a5ec397a25
Autor:
Markus Müschen, Elisabeth Bolton-Gillespie, Richard T. Pomerantz, Sabine Cerny-Reiterer, Peter Valent, Alexander V. Mazin, Tomasz Skorski, Katherine J. Sullivan, Margaret Nieborowska-Skorska
Publikováno v:
Blood. 126:50-50
Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib and nilotinib revolutionized the treatment of chronic myeloid leukemia in chronic phase (CML-CP). However, it is unlikely that TKIs will "cure" a majority of CML patients due to the presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51e00f0466605cdf3d780c1ccc8fed5c
https://doi.org/10.1182/blood.v126.23.50.50
https://doi.org/10.1182/blood.v126.23.50.50
Autor:
Paulina Podszywalow-Bartnicka, Margaret Nieborowska-Skorska, Stephen M. Sykes, Artur Slupianek, Curt I. Civin, Markus Müschen, Elisabeth Bolton-Gillespie, Sabine Cerny-Reiterer, Tomasz Skorski, Grazyna Hoser, Tomasz Stoklosa, Katherine J. Sullivan, Mark D. Minden, Kimberly Cramer-Morales, Kolja Eppert, Chun Zhou, Peter Valent
Publikováno v:
Blood. 124:480-480
Leukemia stem cells (LSCs), and especially quiescent LSCs, have a dual role as tumor initiating and therapy-refractory cells. Therefore, even if anti-tumor treatment clears a disease burden consisting mostly of proliferating leukemia progenitor cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::843225e2ca4e5344e6d1f22f7c7679de
https://doi.org/10.1182/blood.v124.21.480.480
https://doi.org/10.1182/blood.v124.21.480.480
Autor:
Margaret Nieborowska-Skorska, Artur Slupianek, Grazyna Hoser, Elisabeth Bolton-Gillespie, Alexei Tulin, Sabine Cerny-Reiterer, Peter Valent, Markus Muschen, Stephen M. Sykes, Tomasz Skorski
Publikováno v:
Blood. 122:810-810
Leukemia stem cells (LSCs), including quiescent cells, are disease initiating and therapy-refractory cells. Therefore, even if a treatment clears a disease burden consisting mostly of leukemia progenitor cells (LPCs), it usually fails to eradicate LS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d722033e6df32606d780e101c6c739b1
https://doi.org/10.1182/blood.v122.21.810.810
https://doi.org/10.1182/blood.v122.21.810.810
Autor:
Sabine Cerny-Reiterer, Mariusz A. Wasik, Heiko van der Kuip, Tomasz Skorski, Grazyna Hoser, Margaret Nieborowska-Skorska, Christine Richardson, Oliver Hantschel, Yashodhara Dasgupta, Peter Valent, Kanchan Kantekure, Markus Müschen, Darshan Roy, Barbara Górnicka, Tomasz Stoklosa, Elisabeth Bolton-Gillespie, Mateusz Koptyra
Leukemias expressing constitutively activated mutants of ABL1 tyrosine kinase (BCR-ABL1, TEL-ABL1, NUP214-ABL1) usually contain at least 1 normal ABL1 allele. Because oncogenic and normal ABL1 kinases may exert opposite effects on cell behavior, we e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff70f3a4bbe51f76f408395b8c426513
https://infoscience.epfl.ch/record/218252
https://infoscience.epfl.ch/record/218252
